Opinion|Videos|October 2, 2024
Evaluating Quality of Life and Adherence With mCRC Treatment Options
Medical experts discuss the impact of third-line therapies (regorafenib, fruquintinib, FTD/TPI plus bevacizumab) on patient quality of life and share insights on patient adherence to these treatments.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What has been your experience with the impact of these third-line therapy options (regorafenib, fruquintinib, FTD/TPI plus bevacizumab) on a patient’s quality of life?
- What insights can you share related to patient adherence with third-line therapies in metastatic colorectal cancer?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
CMS Final Rule Ends Federal Medicaid, CHIP Funding for Youth Gender-Affirming Care
2
Trump Childhood Vaccine Order: What It Means for Parents and Payers
3
CAR T, Bispecifics Reshape Relapsed Lymphoma Care: Madhav Seshadri, MD
4
OCTOPUS Trial Aims to Speed Access to Rare Sarcoma Drugs
5